Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Payables (2016 - 2025)

Traws Pharma (TRAW) has disclosed Payables for 14 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 6.71% to $5.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 6.71% decrease, with the full-year FY2024 number at $8.2 million, up 45.68% from a year prior.
  • Payables was $5.1 million for Q3 2025 at Traws Pharma, up from $4.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $8.2 million in Q4 2024 to a low of $2.8 million in Q4 2021.
  • A 5-year average of $5.0 million and a median of $4.9 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 42.95% in 2021, then skyrocketed 68.86% in 2023.
  • Traws Pharma's Payables stood at $2.8 million in 2021, then soared by 40.01% to $3.9 million in 2022, then surged by 45.57% to $5.6 million in 2023, then skyrocketed by 45.68% to $8.2 million in 2024, then crashed by 37.64% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Payables are $5.1 million (Q3 2025), $4.8 million (Q2 2025), and $7.7 million (Q1 2025).